| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From Philipps-University, Department of Neurology, Clinical Neuroimmunology Group, Marburg, Germany (B.T., S.S., N.S.); Humboldt University, Institute of Neuroimmunology (J.D.L., F.Z.) and Department of Neurology (J.D.L., R.Z.), Charité, Berlin, Germany; University Hospital Regensburg, Department of Neurology, Regensburg, Germany (A.S., E.R.-K.); Otto-von-Guericke University, Department of Neurology II, Magdeburg, Germany (M.S.); and Georg-August-University, Department of Neuropathology, Göttingen, Germany (W.B.).
Address correspondence and reprint requests to Dr. Norbert Sommer, Philipps-University and University Hospital Giessen and Marburg, Department of Neurology, D-35033 Marburg, Germany sommern{at}med.uni-marburg.de
Background: Chronic immune-mediated demyelinating polyneuropathy (CIP) represents a heterogeneous pool of motor, sensory, sensorimotor, symmetric, or asymmetric syndromes.
Objective: To evaluate published diagnostic classifications and characterize predictors of treatment response.
Methods: One hundred two of 158 patients with a working diagnosis of CIP were included and clinically characterized because they had electrophysiologic and/or histologic evidence of demyelination. The biostatistical profile of patients with symmetric clinical manifestation was analyzed using three proposed classifications (American Academy of Neurology [AAN] criteria, modified AAN criteria, European Federation of Neurological Societies/Peripheral Nerve Society [EFNS/PNS] criteria). Treatment responses to IV immunoglobulins (IVIg) and their positive predictors were investigated.
Results: Sensitivities (0.52 [AAN] vs 0.83 [modified AAN] vs 0.95 [EFNS/PNS]) and negative predictive values (0.68 vs 0.85 vs 0.92) differed markedly, whereas specificities (0.94 vs 0.90 vs 0.96) and positive predictive values (0.89 vs 0.89 vs 0.97) were similar. In CIP patients treated with IVIg, a positive response was found in 62 of 76 (82%). Patients with a monophasic or relapsing–remitting course or a more than twofold CSF protein increase had the highest probability to respond to IVIg, most evident when using the modified AAN criteria.
Conclusions: The European Federation of Neurological Societies/Peripheral Nerve Society criteria for chronic inflammatory demyelinating polyneuropathy improve treatment of patients with chronic immune-mediated demyelinating polyneuropathy, particularly with respect to diagnostic issues. To predict IV immunoglobulin treatment response, the modified American Academy of Neurology criteria are the most valuable classification provided an increased CSF protein level.
*These two authors contributed equally to this work.
Disclosure: Supported by an unrestricted grant from Octapharma AG, Langenfeld, Germany.
Received June 23, 2006. Accepted in final form December 27, 2006.
This article has been cited by other articles:
|
|
 |
|
  H. C. Lehmann, G. Meyer zu Horste, B. C. Kieseier, and H.-P. Hartung Review: Pathogenesis and treatment of immune-mediated neuropathies Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 261 - 281. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Tackenberg, I. Jelcic, A. Baerenwaldt, W. H. Oertel, N. Sommer, F. Nimmerjahn, and J. D. Lunemann Impaired inhibitory Fc{gamma} receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy PNAS, March 24, 2009; 106(12): 4788 - 4792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M P T Lunn and H J Willison Diagnosis and treatment in inflammatory neuropathies J. Neurol. Neurosurg. Psychiatry, March 1, 2009; 80(3): 249 - 258. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
